Cagrilintide: A Synthetic Amylin Analogue for Obesity and Metabolic Research

Cagrilintide, a synthetic long-acting amylin analogue, has attracted significant attention in research settings for its potential effects on appetite regulation, weight reduction, and metabolic homeostasis. Investigated as a non-selective agonist of amylin and calcitonin receptors, this peptide provides a valuable tool for studying obesity and related metabolic disorders.

Overview of Cagrilintide: A Peptide for Metabolic Research

Cagrilintide is a 37-amino-acid synthetic peptide (sequence: {Eicosanedioic acid-γ-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2, with a disulfide bridge between Cys3-Cys8) designed as a long-acting analogue of amylin, a pancreatic hormone co-secreted with insulin. With a molecular formula of C194H312N54O59S2 and a molecular weight of approximately 4409 g/mol, it incorporates lipidation and amino acid substitutions to enhance stability and half-life compared to native amylin or pramlintide PubChem, Cagrilintide. Synthesized for research purposes, cagrilintide is typically administered via subcutaneous injection in preclinical models, with a half-life exceeding 24 hours due to albumin binding

Investigated primarily for its effects on food intake and body weight, cagrilintide has been studied in preclinical models and early-phase clinical trials to elucidate its potential in obesity and type 2 diabetes research. Its dual agonism at amylin receptors (AMYR) and calcitonin G protein-coupled receptors (CTR) makes it a versatile compound for controlled studies. The following sections detail its mechanisms and research findings, emphasizing its role as a research compound.

Mechanism of Action: Appetite and Metabolic Regulation

Cagrilintide exerts its effects by activating AMYR and CTR, modulating appetite, gastric emptying, and energy expenditure, as characterized in preclinical and early clinical studies

• AMYR/CTR Agonism: Cagrilintide activates amylin receptors in homeostatic (e.g., hypothalamus) and hedonic (e.g., reward centers) brain regions, reducing food intake by 25–50% in rat models (3–10 nmol/kg). It also stimulates CTR, enhancing satiety signaling J Pharmacol Exp Ther, AM833 Agonism.

• Appetite Suppression: By slowing gastric emptying and increasing satiety, cagrilintide reduces meal frequency and size, with preclinical studies showing a 48–60-hour suppression of food intake in rats at 3 nmol/kg

• Lipidated Stability: N-terminal lipidation (C20 fatty diacid via γ-Glu linker) enhances albumin binding, extending the half-life and reducing amyloid fibril formation compared to pramlintide Int J Mol Sci, Amylin Research.

• Pharmacokinetics: In animal models, cagrilintide (10 nmol/kg, subcutaneous) achieves sustained plasma levels for several days, with peak concentrations within 4–6 hours, supporting once-weekly dosing in research protocols

Preclinical studies in obese rats demonstrated a 10–15% body weight reduction after 26 days of cagrilintide (2.4 mg/kg/week), while phase 2 trials in humans (0.3–4.5 mg/week) reported 7–10% weight loss over 26 weeks Lancet, Cagrilintide Weight Management. These findings highlight cagrilintide’s research potential.

Research Applications of Cagrilintide: Insights from Preclinical and Clinical Studies

Cagrilintide’s role in research focuses on its effects on appetite regulation, weight loss, and metabolic homeostasis, providing data for obesity and diabetes studies. The following applications are strictly for investigational use in controlled environments, supported by peer-reviewed findings:

Weight Loss and Appetite Regulation

Preclinical and clinical studies underscore cagrilintide’s ability to reduce body weight and food intake:

• A 25–50% reduction in food intake in rat models (1–10 nmol/kg) over 48–60 hours, driven by AMYR-mediated satiety

• 10% body weight reduction in obese mice after 26 days (2.4 mg/kg/week), with dose-dependent effects J Obes Metab Syndr, Amylin Treatment.

• Phase 2 trials reported 7.8% weight loss in humans with obesity (4.5 mg/week, 26 weeks) compared to 3% with placebo Lancet, Cagrilintide Weight Management.

Type 2 Diabetes and Glycemic Control

Cagrilintide’s effects on glycemic parameters are studied in combination with GLP-1 agonists:

• In a phase 2 trial, cagrilintide (2.4 mg/week) co-administered with GLP-1 (2.4 mg/week) achieved 89% time-in-range for glycemic control in type 2 diabetes patients, compared to 76% with GLP-1 alone Lancet, CagriSema Trial.

• Preclinical models showed a 15–20% reduction in fasting glucose levels in diabetic rats (10 nmol/kg) Int J Mol Sci, Amylin Research.

• Potential for studying synergistic effects with GLP-1 agonists in metabolic regulation Cardiol Rev, Cagrilintide Obesity.

Metabolic Pathway Research

Cagrilintide serves as a model for studying amylin and calcitonin receptor signaling:

• 20–30% increased cAMP production in AMYR-expressing cell lines, facilitating receptor signaling studies J Pharmacol Exp Ther, AM833 Agonism.

• Investigation of gastric emptying mechanisms, with 15–20% delayed gastric motility in rodent models J Obes Metab Syndr, Amylin Treatment.

• Comparison to pramlintide, showing improved stability and reduced fibril formation.

Neurological Appetite Regulation

Preclinical data suggest cagrilintide’s effects on brain appetite centers:

• 15–20% increased neuronal activation in hypothalamic and reward regions in rats, linked to satiety signaling Int J Mol Sci, Amylin Research.

• Potential for studying hedonic eating behaviors, though human data is limited Cardiol Rev, Cagrilintide Obesity.

• No significant cognitive effects observed, with further research needed.

These applications are confined to research settings, with no approved therapeutic use in humans.

Research Populations and Study Designs

Cagrilintide’s research applications target specific investigational populations and study designs:

• Preclinical Researchers: Scientists studying obesity, type 2 diabetes, or appetite regulation use cagrilintide in rodent models to explore AMYR/CTR signaling.

• Metabolic Disease Investigators: Researchers examining weight loss or glycemic control employ cagrilintide to elucidate synergistic effects with GLP-1 agonists Lancet, CagriSema Trial.

• Biomedical Scientists: Those developing novel anti-obesity agents compare cagrilintide’s efficacy to other peptides J Obes Metab Syndr, Amylin Treatment.

Typical study designs involve obese or diabetic rodent models dosed at 1–10 nmol/kg for 1–4 weeks, measuring food intake, body weight, and glycemic markers. Human trials (phase 1b/2) used 0.3–4.5 mg/week for 20–32 weeks, assessing weight loss and safety Lancet, Cagrilintide Weight Management.

Research Limitations and Considerations

Several limitations and considerations apply to cagrilintide research:

• Limited Clinical Data: Phase 2 trials show efficacy, but phase 3 data and long-term outcomes are pending, limiting therapeutic extrapolation Lancet, CagriSema Trial.

• Regulatory Status: Cagrilintide is not approved by the FDA or any regulatory body for human use and is designated for research purposes only.

• Side Effect Profile: Preclinical studies report no significant adverse effects at 1–10 nmol/kg. Human trials noted mild gastrointestinal effects (e.g., nausea in 20–47% of participants) and injection site reactions (<5%) Lancet, Cagrilintide Weight Management.

• Dosing Variability: Research doses (1–10 nmol/kg in animals, 0.3–4.5 mg/week in humans) lack standardization, requiring precise protocols J Pharmacol Exp Ther, AM833 Agonism.

• Long-Term Safety: No long-term data exist, necessitating caution in extended research protocols Cardiol Rev, Cagrilintide Obesity.

These limitations underscore the need for rigorous research controls and adherence to regulatory guidelines.

Conclusion: A Promising Tool for Obesity and Metabolic Research

Cagrilintide, a synthetic long-acting amylin analogue, offers significant potential as a research tool for studying appetite regulation, weight loss, and glycemic control. Preclinical studies demonstrate a 25–50% reduction in food intake, 10–15% body weight loss, and enhanced glycemic control, while phase 2 trials confirm 7–10% weight reduction in humans. For researchers investigating obesity, type 2 diabetes, or AMYR/CTR signaling, cagrilintide is a precise instrument for controlled studies. However, its investigational status, limited clinical data, and regulatory restrictions confine its use to research settings.

Key Citations

• Cagrilintide structure and properties

• Cagrilintide development

• Cagrilintide weight management trial

• CagriSema phase 2 trial

• AM833 receptor agonism

• Amylin in obesity treatment

• Cagrilintide obesity review

• Amylin neuroendocrine research

Legal Disclaimer

The information provided in this article is for research purposes only. Cagrilintide is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for human consumption or therapeutic use. It is intended solely for investigational use in controlled laboratory settings by qualified researchers. Protide Health does not endorse or promote the use of cagrilintide in humans or animals outside of approved research protocols. Researchers must comply with all applicable local, state, and federal regulations, including obtaining necessary approvals for experimental use. Consult with regulatory authorities before initiating any research involving cagrilintide.

Additional information

Weight1 lbsDimensions1 × 1 × 1 in

Overview of Cagrilintide: A Peptide for Metabolic Research

Cagrilintide is a 37-amino-acid synthetic peptide (sequence: {Eicosanedioic acid-γ-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2, with a disulfide bridge between Cys3-Cys8) designed as a long-acting analogue of amylin, a pancreatic hormone co-secreted with insulin. With a molecular formula of C194H312N54O59S2 and a molecular weight of approximately 4409 g/mol, it incorporates lipidation and amino acid substitutions to enhance stability and half-life compared to native amylin or pramlintide PubChem, Cagrilintide. Synthesized for research purposes, cagrilintide is typically administered via subcutaneous injection in preclinical models, with a half-life exceeding 24 hours due to albumin binding

Investigated primarily for its effects on food intake and body weight, cagrilintide has been studied in preclinical models and early-phase clinical trials to elucidate its potential in obesity and type 2 diabetes research. Its dual agonism at amylin receptors (AMYR) and calcitonin G protein-coupled receptors (CTR) makes it a versatile compound for controlled studies. The following sections detail its mechanisms and research findings, emphasizing its role as a research compound.